explore -WSS

explore

author：entertainment 2025-10-02 22:23:52 - browse：47

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

explore

WSS

New safety details link Apellis eye drug to rare cases of blindness

5 important ways Henrietta Lacks changed medical science

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Trump indictment: Who are the 'co

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

With trial win, GSK could get blood cancer drug back on market

Wikipedia

explore

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Activists slam private health insurers over coverage restrictions

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Wildfire smoke exposes gaps in outdoor worker protections

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Sports medicine is finally prioritizing gender equality

How to increase colonoscopy rates? Looks like an AI can help

Jerome Adams on the need for new antivirals for Covid

The high personal cost of affirmative action for Black doctors

focus

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Mega Millions pot grows to $1.25 billion after no winner

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Sage hopes for a blockbuster in antidepressant now before FDA

Shifting the focus from loneliness to social health

focus

focus

explore

hotspot